Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ensysce Biosciences, Inc. - Common Stock (NQ:ENSC)

0.8901 -0.0299 (-3.25%)
Streaming Delayed Price Updated: 11:46 AM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ensysce Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
News headline image
Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid
Via ACCESS Newswire
News headline image
Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
Via ACCESS Newswire
News headline image
Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach
Via ACCESS Newswire
News headline image
Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs
Via ACCESS Newswire
News headline image
Ensysce Biosciences Reports Third Quarter 2025 Financial Results
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection
Via ACCESS Newswire
News headline image
Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025
Via ACCESS Newswire
News headline image
Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium
Via ACCESS Newswire
News headline image
Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025
Via ACCESS Newswire
News headline image
Ensysce Biosciences Narrows Loss in Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback
Via ACCESS Newswire
News headline image
These stocks that are showing activity before the opening bell on Wednesday. ↗
Before the opening bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse
Via ACCESS Newswire
News headline image
Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2
Via ACCESS Newswire
News headline image
Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Ensysce Biosciences Reports First Quarter 2025 Financial Results
Via ACCESS Newswire
News headline image
Ensysce Biosciences Bolsters Management Team with Regulatory Expert
Via ACCESS Newswire
News headline image
Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why ServiceNow Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Top movers in Wednesday's after hours session ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why ↗
Ensysce Biosciences rises after patent notice for PF9001, a methadone prodrug aimed at safer opioid use with overdose protection technology. 
Via Benzinga
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.